nach oben

Erschienen in:

01.05.2007 | Original Paper

Health-related quality of life in HIV-1-infected patients on HAART: a five-years longitudinal analysis accounting for dropout in the APROCO-COPILOTE cohort (ANRS CO-8)

verfasst von: Camelia Protopopescu, Fabienne Marcellin, Bruno Spire, Marie Préau, Renaud Verdon, Dominique Peyramond, François Raffi, Geneviève Chêne, Catherine Leport, Maria-Patrizia Carrieri

Erschienen in: Quality of Life Research | Ausgabe 4/2007

Einloggen, um Zugang zu erhalten

Abstract

Background

The long-term efficacy of Highly Active Antiretroviral Therapies (HAART) has enlightened the crucial role of health-related quality of life (HRQL) among HIV-infected patients. However, any analysis of such extensive longitudinal data necessitates a suitable handling of dropout which may correlate with patients–health status.

Methods

We analysed the HRQL evolution over 5 years for 1,000 patients initiating a protease inhibitor (PI)-containing therapy, using MOS SF-36 physical (PCS) and mental (MCS) scores. In parallel with a classical separate random effects model, we used a joint parameter-dependent selection model to account for non-ignorable dropout.

Results

HRQL evolved according to a two-phase pattern, characterized by an initial improvement during the year following HAART initiation and a relative stabilization thereafter. Immunodepression and self-reported side effects were found to be negative predictors of both PCS and MCS scores. Hepatitis C virus coinfection and AIDS clinical stage were found to affect physical HRQL. Results were not significantly altered when accounting for dropout.

Conclusion

Such results, obtained on a large sample of HIV-infected patients with extensive follow-up, underline the need for a regular monitoring of patients–immunological status and for a better management of their experience with hepatitis C and HAART.

Nur mit Berechtigung zugänglich

Note that there is no principal effect for the “Number of self-reported symptoms of lipodystrophy–in Table 3, as lipodystrophy symptoms were absent at M0. The coefficient of the first slope is used in this case for the interpretation.

Palella, F. J., Jr., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., et al. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. New England Journal of Medicine, 338, 853–60.CrossRefPubMed

Little, R., & Rubin, D. (2002). Statistical analysis with missing data.

Laird, N. M. (1988). Missing data in longitudinal studies. Statistics in Medicine, 7, 305–15.CrossRefPubMed

Vonesh, E. F., Greene, T., & Schluchter, M. D. (2006). Shared parameter models for the joint analysis of longitudinal data and event times. Statistics in Medicine, 15, 143–63.CrossRef

Hogan, J. W., Lin, X., & Herman, B. (2004). Mixtures of varying coefficient models for longitudinal data with discrete or continuous nonignorable dropout. Biometrics, 60, 854–64.CrossRefPubMed

Lin, D. Y., & Ying, Z. (2003). Semiparametric regression analysis of longitudinal data with informative drop-outs. Biostatistics, 4, 385–98.CrossRefPubMed

Hu, C., & Sale, M. E. (2003). A joint model for nonlinear longitudinal data with informative dropout. Journal of Pharmacokinetics and Pharmacodynamics, 30, 83–03.CrossRefPubMed

Guo, X., & Carlin, B. P. (2004). Separate and joint modeling of longitudinal and event time data using standard computer packages. The American Statistician, 58, 1–.CrossRef

Carrieri, P., Spire, B., Duran, S., Katlama, C., Peyramond, D., Francois, C., et al. (2003). Health-related quality of life after 1 year of highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 32, 38–7.PubMed

10.

Carrieri, M. P., Leport, C., Protopopescu, C., Cassuto, J. P., Bouvet, E., Peyramond, D., et al. (2006), Factors associated with nonadherence to highly active antiretroviral therapy: A 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase. Journal of Acquired Immune Deficiency Syndromes, 41, 477–85.CrossRefPubMed

11.

Ware, J. E., Jr., & Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care, 30, 473–83.CrossRefPubMed

12.

McHorney, C. A., Ware, J. E., Jr., & Raczek, A. E. (1993). The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Medical Care, 31, 247–63.CrossRefPubMed

13.

McHorney, C. A., Ware, J. E., Jr., Lu, J. F., & Sherbourne, C. D. (1994). The MOS 36-item Short-Form Health Survey (SF-36): III Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Medical Care, 32, 40–6.CrossRefPubMed

14.

Ware, J. E., Jr., Keller, S. D., Gandek, B., Brazier, J. E., & Sullivan, M. (1995). Evaluating translations of health status questionnaires. Methods from the IQOLA project. International Quality of Life Assessment. International Journal of Technology Assessment in Health Care, 11, 525–51.CrossRefPubMed

15.

Leplege, A., Mesbah, M., & Marquis, P. (1995). [Preliminary analysis of the psychometric properties of the French version of an international questionnaire measuring the quality of life: The MOS SF-36 (version 1.1)]. Revue d Epidemiologie et de Sante Publique, 43, 371–79.PubMed

16.

Prentice, R. L., & Gloeckler, L. A. (1978). Regression analysis of grouped survival data with application to breast cancer data. Biometrics, 34, 57–7.CrossRefPubMed

17.

Henderson, R., Diggle, P., & Dobson, A. (2000). Joint modelling of longitudinal measurements and event time data. Biostatistics, 1, 465–80.CrossRefPubMed

18.

SAS/STAT 9.1 (2004). User’s Guide. Cary, NC, SAS Institute Inc: SAS Publishing.

19.

Furher, R., & Rouillon, F. (1989). La version française de l’échelle CES-D. Description and translation of the auto-evaluation (in French). Psychiatrie et Psychobiologie, 4, 163–66.

20.

Bissell, D., Paton, A., & Ritson, B. (1982). ABC of alcohol. Help: Referral. British Medical Journal (Clinical Research Ed), 284, 495–97.CrossRef

21.

Nieuwkerk, P. T., Gisolf, E. H., Colebunders, R., Wu, A. W., Danner, S. A., & Sprangers, M. A. (2000). Quality of life in asymptomatic- and symptomatic HIV infected patients in a trial of ritonavir/saquinavir therapy. The Prometheus Study Group. Acquired Immune Deficiency Syndromes, 14, 181–87.

22.

Cohen, C., Revicki, D. A., Nabulsi, A., Sarocco, P. W., & Jiang, P. (1998). A randomized trial of the effect of ritonavir in maintaining quality of life in advanced HIV disease. Advanced HIV Disease Ritonavir Study Group. Acquired Immune Deficiency Syndromes, 12, 1495–502.

23.

Carr, A., Chuah, J., Hudson, J., French, M., Hoy, J., Law, M., et al. (2000). A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: The OzCombo1 study. Acquired Immune Deficiency Syndromes, 14, 1171–180.

24.

Nieuwkerk, P. T., Gisolf, E. H., Reijers, M. H., Lange, J. M., Danner, S. A., & Sprangers, M. A. (2001). Long-term quality of life outcomes in three antiretroviral treatment strategies for HIV-1 infection. Acquired Immune Deficiency Syndromes, 15, 1985–991.

25.

Burgoyne, R. W., Rourke, S. B., Behrens, D. M., & Salit, I. E. (2004). Long-term quality-of-life outcomes among adults living with HIV in the HAART era: The interplay of changes in clinical factors and symptom profile. Acquired Immune Deficiency Syndromes Behavior, 8, 151–63.

26.

Burgoyne, R., & Renwick, R. (2004). Social support and quality of life over time among adults living with HIV in the HAART era. Social Science and Medicine, 58, 1353–366.CrossRefPubMed

27.

Eriksson, L. E., Bratt, G. A., Sandstrom, E., & Nordstrom, G. (2005). The two-year impact of first generation protease inhibitor based antiretroviral therapy (PI-ART) on health-related quality of life. Health Quality of Life Outcomes, 3, 32.CrossRef

28.

Campsmith, M. L., Nakashima, A. K., & Davidson, A. J. (2003). Self-reported health-related quality of life in persons with HIV infection: Results from a multi-site interview project. Health Quality of Life Outcomes, 1, 12.CrossRef

29.

Jia, H., Uphold, C. R., Wu, S., Chen, G. J., & Duncan, P. W. (2005). Predictors of changes in health-related quality of life among men with HIV infection in the HAART era. Acquired Immune Deficiency Syndromes Patient Care STDS Patient Care STDS, 19, 395–05.

30.

Hogg, R. S., Yip, B., Chan, K. J., Wood, E., Craib, K. J., O’shaughnessy, M. V., & Montaner, J. S. (2001). Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA, 286, 2568–577.CrossRefPubMed

31.

Bonfanti, P., Valsecchi, L., Parazzini, F., Carradori, S., Pusterla, L., Fortuna, P., et al. (2000). Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group. Journal of Acquired Immune Deficiency Syndromes, 23, 236–45.PubMed

32.

Fellay, J., Boubaker, K., Ledergerber, B., Bernasconi, E., Furrer, H., Battegay, M., et al. (2001). Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet, 358, 1322–327.CrossRefPubMed

33.

Ammassari, A., Murri, R., Pezzotti, P., Trotta, M. P., Ravasio, L., De Longis, P., et al. (2001). Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. Journal of Acquired Immune Deficiency Syndromes, 28, 445–49.PubMed

34.

Duran, S., Spire, B., Raffi, F., Walter, V., Bouhour, D., Journot, V., et al. (2001). Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clinical Trials, 2, 38–5.CrossRefPubMed

35.

Bury, M. (1991). The sociology of chronic illness: A review of research and prospects. Sociology of Health and Illness, 13, 451–68.CrossRef

36.

Foster, G. R., Goldin, R. D., & Thomas, H. C. (1998). Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology, 27, 209–12.CrossRefPubMed

37.

Rodger, A. J., Jolley, D., Thompson, S. C., Lanigan, A., & Crofts, N. (1999). The impact of diagnosis of hepatitis C virus on quality of life. Hepatology, 30, 1299–301.CrossRefPubMed

38.

Preau, M., Leport, C., Salmon-Ceron, D., Carrieri, P., Portier, H., Chene, G., et al. (2004). Health-related quality of life and patient–provider relationships in HIV-infected patients during the first three years after starting PI-containing antiretroviral treatment. Acquired Immune Deficiency Syndromes Care, 16, 649–61.

39.

Cederfjall, C., Langius-Eklof, A., Lidman, K., & Wredling, R. (2001). Gender differences in perceived health-related quality of life among patients with HIV infection. Acquired Immune Deficiency Syndromes Patient Care STDS, 15, 31–9.

40.

Mrus, J. M., Williams, P. L., Tsevat, J., Cohn, S. E., & Wu, A. W. (2005). Gender differences in health-related quality of life in patients with HIV/AIDS. Quality of Life Research, 14, 479–91.CrossRefPubMed

41.

Nicholas, P. K., Kirksey, K. M., Corless, I. B., & Kemppainen, J. (2005). Lipodystrophy and quality of life in HIV: Symptom management issues. Applied Nursing Research, 18, 55–8.CrossRefPubMed

42.

Collins, E., Wagner, C., & Walmsley, S. (2000). Psychosocial impact of the lipodystrophy syndrome in HIV infection. Acquired Immune Deficiency Syndromes Read, 10, 546–50.

43.

Préau, M., Bouhnik, A., Spire, B., Leport, C., Saves, M., Pïcard, O., et al. (2006). Health related quality of life and lipodystrophy syndrome among HIV-infected patients. Encephale, 32, 713–19.CrossRefPubMed

44.

Hsiung, P. C., Fang, C. T., Chang, Y. Y., Chen, M. Y., Wang, J. D. (2005). Comparison of WHOQOLbREF and SF-36 in patients with HIV infection. Quality of Life Research, 14, 141–50.CrossRefPubMed

45.

Monnete, G., Shao, Q., & Kwan, E. (2002). A first look at multilevel models. In S.C.S. Institute for Social Research. York University: Institute for Social Research. Statistical Consulting Service, York University.

46.

Allison, P. D. (1995). Survival analysis using the SAS system: A practical guide. The SAS Institute, Cary, NC.

47.

Allison, P. D. (1982). Discrete-time methods for the analysis of event histories. Sociological Methodology, 15, 61–8.CrossRef

48.

Jenkins, S. P. (1995). Easy estimation methods for discrete-time duration models. Oxford Bulletin of Economics and Statistics, 57, 129–38.

49.

Jenkins, S. P. (1997). Estimation of discrete time (grouped duration data) proportional hazards models: pgmhaz. Stata Technical Bulletin Reprints, STB 17, 1–2.

50.

Jenkins, S. P. (2005). Survival analysis. In Institute for Social and Economic Research, University of Essex.

51.

Zewotir, T., & Galpin, J. S. (2005). Influence diagnostics for linear mixed models. Journal of Data Science, 3, 153–77.

Titel: Health-related quality of life in HIV-1-infected patients on HAART: a five-years longitudinal analysis accounting for dropout in the APROCO-COPILOTE cohort (ANRS CO-8)
verfasst von: Camelia Protopopescu
Fabienne Marcellin
Bruno Spire
Marie Préau
Renaud Verdon
Dominique Peyramond
François Raffi
Geneviève Chêne
Catherine Leport
Maria-Patrizia Carrieri
Publikationsdatum: 01.05.2007
Verlag: Springer Netherlands
Erschienen in: Quality of Life Research / Ausgabe 4/2007
Print ISSN: 0962-9343
Elektronische ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-006-9151-7

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2007

Factors affecting health-related quality of life in women with recurrent breast cancer in Korea

Are persons with physical disabilities who participate in society healthier and happier? Structural equation modelling of objective participation and subjective well-being

The Affectometer 2: a measure of positive mental health in UK populations

Burden of restless legs syndrome on health-related quality of life

Documenting the rationale and psychometric characteristics of patient reported outcomes for labeling and promotional claims: the PRO Evidence Dossier

The role of coping strategies in quality of life of adolescents with asthma